Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U5OE
|
||||
| Former ID |
DAP000311
|
||||
| Drug Name |
Loxapine
|
||||
| Synonyms |
Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Watson Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H18ClN3O
|
||||
| InChI |
InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
|
||||
| InChIKey |
XJGVXQDUIWGIRW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 1977-10-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9315, 4964194, 7849399, 7979814, 8152490, 10512454, 11342094, 11362277, 11363249, 11365811, 11368373, 11373078, 11376535, 11466160, 11467280, 11485550, 11485879, 11487679, 11489553, 11491645, 11494169, 14875092, 29223078, 46505047, 47216951, 47216952, 47216953, 47291295, 47440444, 47515494, 47589159, 47589160, 48185160, 48259433, 48416188, 49698364, 49846685, 49962613, 50103874, 50104024, 50104025, 50104026, 50738126, 56352861, 57322072, 61212540, 85209777, 85787876, 85789426, 90341467
|
||||
| ChEBI ID |
ChEBI:50841
|
||||
| SuperDrug ATC ID |
N05AH01
|
||||
| SuperDrug CAS ID |
cas=001977102
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.